According to an Oct 3 announcement, the two parties signed a memorandum of understanding (MOU) on Oct 1 outlining the goals of their collaboration.
The Agency for Science, Technology and Research (A*STAR) and US bioplatform innovation company Flagship Pioneering will jointly commit up to $100 million ($129.41 million) over the next five years to spur biotech innovation in Singapore and the Asia Pacific.
Flagship is best known for its role in backing Moderna, which created a widely-used Covid-19 vaccine.
